September 15, 2022

Pliant Therapeutics

Pliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors

September 14, 2022

Nurix

Nurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of Directors

September 07, 2022

Voyager Therapeutics

Voyager Therapeutics Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs

September 02, 2022

Revolution Medicines

Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire

September 01, 2022

Pliant Therapeutics

Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

Load More

Sign up for weekly portfolio news.